1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Tuberous Sclerosis 2: new trials by email Literature Review of Tuberous Sclerosis 2 trials Research Report on Tuberous Sclerosis 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures GWP42003-P - Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome | Phase 3 | Terminated | Jazz Pharmaceuticals | 3 | 2021-05-19 | 2025-10-31 |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Everolimus (RAD001), Everolimus Placebo - Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM) | Phase 3 | Completed | Novartis Pharmaceuticals | 118 | 2009-04-01 | 2017-02-17 |
Seizures (2) · Tuberous Sclerosis (2) · Angiomyolipoma (1) · Astrocytoma (1) · Epilepsies, Myoclonic (1) · Epilepsy (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lennox Gastaut Syndrome (1) · Lymphangioleiomyomatosis (1) · Spasms, Infantile (1) · Tuberous Sclerosis 1 (1)
Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hamartoma (2) · Heredodegenerative Disorders, Nervous System (2) · Malformations of Cortical Development (2) · Malformations of Cortical Development, Group I (2) · Neoplasms (2) · Neoplasms, Multiple Primary (2) · Neoplastic Syndromes, Hereditary (2) · Nervous System Diseases (2) · Nervous System Malformations (2) · Neurocutaneous Syndromes (2) · Neurodegenerative Diseases (2) · Neurologic Manifestations (2)
Cannabidiol (1) · Everolimus (1)
Jazz Pharmaceuticals (1) · Novartis Pharmaceuticals (1)
Italy (2) · Spain (2) · United States (2) · Canada (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · Poland (1) · Russia (1) · United Kingdom (1)
PMID 26156073, PMID 29023494, PMID 30053159, PMID 30192751
2008 (1)